Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-05-17
2005-05-17
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093210, C536S023500, C435S320100, C435S325000, C435S455000, C435S810000
Reexamination Certificate
active
06894031
ABSTRACT:
Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C), which has the ability to regulate endogenous pituitary, tumor transforming gene (PTTG) expression and/or function in a dominant negative manner. In some embodiments, the invention is directed to gene-based treatments that deliver PTTG-C-related polynucleotides to mammalian cells, whether in vitro or in vivo, to inhibit the endogenous expression of PTTG. Other embodiments are directed to peptide-based treatments that deliver PTTG-C peptide molecules to the cells, which inhibit endogenous PTTG expression and/or PTTG function. Additional embodiments directed to a method of inhibiting tumor angiogenesis, in vivo, are also disclosed. Also disclosed are compositions useful for inhibiting neoplastic cellular proliferation and/or transformation and tumor angiogenesis, including compositions comprising a PTTG carboxy-terminal peptide or comprising a chimeric or fusion protein that contains a first PTTG carboxy-terminal peptide segment and a second cellular uptake-enhancing and/or importation-competent peptide segment. Also disclosed are compositions comprising a PTTG carboxy-terminal-related polynucleotide, including compositions comprising expression vectors containing the PTTG-C-related polynucleotides. Kits comprising the inventive compositions are also disclosed for the treatment of neoplastic cellular proliferation in vitro or in vivo. Isolated PTTG-C peptides and PTTG-C-related polynucleotides are also disclosed, as are anti-PTTG-C-specific antibodies.
REFERENCES:
patent: WO 9009442 (1990-08-01), None
patent: WO 9325712 (1993-12-01), None
patent: WO 9822587 (1998-05-01), None
Verma et al., 1997, Nature, vol. 389, p. 239-242.*
Gorecki, D., 2001, Expert Opin. Emerging Drugs, vol. 6, No. 2, p. 187-198.*
Ohgi et.al.; Expression of RNase Rh from Rhizopus niveus in Yeast and Characerization of the Secreted Proteins, 1991, J Biochem 109: 775-785.*
Kaye et.al.; A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding, 1990, Proc. Natl. Acad. Sci., vol. 87: 6922-6926.*
Rudinger; Characteristics of the amino acids as components of a peptide hormone sequence, 1976, Peptide Hormones: 1-7.*
Crystal; Transfer of Genes to Humans: Early Lessons and Obstacles to Success, 1995, Science, vol. 270: 404-410.*
Deonarain; Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents 8(1):53-69.*
Eck et.al.; Gene-Based Therapy, 1996, The Pharmacological Basis of Therapeutics:77-101.*
Accession No. AAT21011, 1996.*
Accession No. H66067, 1995.*
PCT International Search Report—PCT/US 97/21463, Nov. 22, 1997.
Marra, M., et al., “The WashU-HHMI Mouse EST project, AC W81747”, EMBL Database, Jun. 27, 1996, Heidelberg, XP002066845.
Hillier L., et al., The WashU-Merck EST project, AC AA007646, EMBL Database, Jul. 28, 1996, Heidelberg, XP002066846.
Holton, T., et al., “ACQ57612”, EMBL Database, Sep. 5, 1994, Heidelberg, XP002066847.
Nippon Telegraph and Telephone Corp.: “ACQ75553”, EMBL Database, Aug. 4, 1995, Heidelberg, XP002066848.
Gonsky, R., et al., “Transforming DNA Sequences Present in Human Prolactin-Secreting Pituitary Tumors”, Molec. Endocrin., 5(11): 1687-1695, Nov. 1991.
Pei, L., et al., “Isolation and Characterization of a Pituitary Tumor-Transforming Gene (PTTG)”, Molec. Endocrin., 11(4): 433-441, Apr. 1997.
Shimon, I., et al., “Genetic Basis of Endocrine Disease”, J. Clin. Endocrin. And Metab., 82(6): 1675-1681, Jun. 1997.
Chen, L., et al., “Identification of the human pituitary tumor transforming gene (hPTTG) family: molecular structure, expression, and chromosomal localization.”, 1: Gene 2000, May 2; 248 (102): 41-50. Abstract Only.
Heaney, A.P., “Expression of pituitary-tumor transforming gene in colorectal tumours”, 1: Lancet Feb. 26, 2000; 355(9205): 716-9.
Heaney, A.P., “Early Involvement of Estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis”, 1: Nat Med 1999, Nov.; 5(11): 1317-21.
Suhardja, A.S., et al., “Molecular pathogenesis of pituitary adenomas: a review.”, Acta Neurochir (Wein) 1999; 141(7): 729-36. Abstract Only.
Ren, R., et al., “Identification of a ten-amino acid proline-rich SH3 binding site.”, Science Feb. 19, 1993; 259(5098): 1157-61. Abstract Only.
Liu, X., et al., “The v-Src SH3 domain binds phosphatidylinositol 3′-kinase.” Mol Cell Biol Sep. 1993; 13(9): 5225-32. Abstract Only.
Gout, I., et al., “The GTPase dynamin binds to and is activated by a subset of SH3 domains.” Cel Oct 8, 1993; 75(1): 25-36.
Yu, H., et al., “Solution structure of the SH3 domain of Src and identification of its ligan-binding site.” Science Dec. 4, 1992; 258(5088): 1665-8. Abstract Only.
Lee, I.A., et al., “Cloning and expression of human cDNA encoding human homologue of pituitary tumor transforming gene.”, Biochem Mol. Biol Int May 1999; 47(5): 891-7. Abstract Only.
Zou, H., et al., “Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis.”, Science Jul. 16, 1999; 285(5426): 418-22. Abstract Only.
Zhang, X., et al., “Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas.” J Clin Endocrinol Metab Feb. 1999; 84(2): 761-7.
Prezant, T.R., et al., “An intronless homolog of human proto-oncogene hPTTg is expressed in pituitary tumors; evidence for hPTTG family.”, J Clin Endocrinol Metab Mar. 1999; 84(3): 1149-52.
Fujimoto, N., et al., “Establishment of an estrogen responsive rat pituitary cell sub-line MtTe-2.” Endocr J Jun. 1999; 46(3): 389-96. Abstract Only.
Ramos-Morales, F., et al., “Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product.”, Oncogene Jan. 20, 2000; 19(3): 403-9. Abstract Only.
McCabe C.J., et al., “PTTG—a new pituitary tumour transforming gene.”, J Endocrinol Aug. 1999; 162(2): 163-6. Abstract Only.
Kakar, S.S., “Molecular cloning, genomic organization, and identification of the promoter for the human pituitary tumor transforming gene (PTTG).”, Gene Nov. 29, 1999; 240(2): 317-24. Abstract Only.
Dominguez, A., et al., “hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a activation function of hPTTG.”, Oncogene Oct. 29, 1998; 17(17): 2187-93. Abstract Only.
Pei, L., “Pituitary tumor-transforming gene protein associates with ribosomal protein S10 and a novel human homologue of DnaJ in testicular cells.”, J Biol Chem Jan. 29, 1999; 274(5): 3151-8.
Saez, C., et al., “hpttg is over-expressed in pituitary-adenomas and other primary epithelial neoplasias.”, Oncogene Sep. 23, 1999; 18(39): 5473-6, Abstract Only.
Pei, L., “Genomic Organization and identification of an enhancer element containing binding sites for multiple proteins in rat pituitary tumor-transforming gene.”, J Biol Chem Feb. 27, 1998; 273(9): 5219-25.
Wang, Z., et al., “Characterization of the murine pituitary tumor transforming gene (PTTG) and its promoter.”, Endocrinology Feb. 2000; 141(2): 763-71.
Zhang, X., et al., “Structure, expression, and function of human pituitary tumor-transfoming gene (PTTG).”, Mol. Endocrinol Jan. 1999; 13(1): 156-66.
Heaney, Anthony, P., et al., “Pituitary tumor transforming gene: a novel factor is pituitary tumour formation,” Balliere's Clinical Endocrinology and Metabolism, vol. 13, No. 3, pp. 367-380, 1999.
Dominguez, Africa et al., hpttg, a human homologue for rat pttg, is overexpressed in hematop
Horwitz Gregory A.
Melmed Shlomo
Zhang Xun
Cedars-Sinai Medical Center
Chen Shin-Lin
Pillsbury & Winthrop LLP
LandOfFree
Pituitary tumor transforming gene (PTTG) carboxy-terminal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pituitary tumor transforming gene (PTTG) carboxy-terminal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pituitary tumor transforming gene (PTTG) carboxy-terminal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3463729